6-K

UNITEDSTATES

SECURITIESAND EXCHANGE COMMISSION

Washington,D.C. 20549

Form6-K

REPORTOF FOREIGN PRIVATE ISSUER

PURSUANTTO RULE 13a-16 OR 15d-16

UNDERTHE SECURITIES EXCHANGE ACT OF 1934

Forthe month of September 2025

CommissionFile Number: 001-40678

EUDAHealth Holdings Limited

(Exact Name of Registrant as Specified in its Charter)

60 Kaki Bukit Place, #03-01

Eunos Techpark, Singapore 415979.

(Address of Principal Executive Offices and Zip Code)

Registrant’s telephone number, including area code: +65 6327 1110.

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

OtherEvents.

On September 4, 2025, EUDA Health Holdings Limited issued the press release filed herewith as Exhibit 99.1.

Exhibits

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

Exhibit99.1

EUDA Strategically Expands into T-Cell Immunotherapy – Strengthening Its Stem Cell Therapy Portfolio

SINGAPORE,Sept. 04, 2025 (GLOBE NEWSWIRE) — EUDA Health Holdings Limited (“EUDA” or the “Company”) (NASDAQ: EUDA), a leading Singapore-based non-invasive healthcare provider in Asia with a focus on Singapore, Malaysia, and China, today announced that it has secured distribution rights for T-cell immunotherapies in Malaysia developed by Shenzhen Inno Immune Co. Ltd. (“Shenzhen Inno”), a developer of autologous cellular therapeutic and customized medicines for a wide range of diseases in China. These T-cell immunotherapies are designed to restore and rebuild the body’s natural defenses.

This marks EUDA’s second major step into advanced cell therapy this year, following its April 2025 distribution partnership with GuangdongCell Biotech Co., Ltd., a leader in autologous stem cell therapies in China. Together, these strategic actions reflect EUDA’s accelerated push into the regenerative and longevity medicine space, reinforcing its commitment to deliver science-driven, non-invasive solutions for aging and chronic conditions.

According to the terms of the agreement, Guangdong Key Lock Health Management Co., Ltd. (“Keylock”), a long-term strategic partner to both Shenzhen Inno and EUDA and distributor of Shenzhen Inno’s stem cell therapies and regenerative medicine, has granted CKHealth Plus Sdn Bhd, a wholly-owned subsidiary of EUDA, the right to market and sell to EUDA customers in Malaysia T-cell immunotherapies provided by Shenzhen Inno in China.

The T-cell immunotherapy package will retail at USD 8,000 per treatment, which is a fraction of the traditional cost in other markets in the region. This pricing strategy reflects a clinically advanced, personalized approach to long-term immune system support while making cutting-edge immunotherapy more accessible across Malaysia by addressing the historical cost barriers that have limited access to such treatments.

ShenzhenInno brings significant scientific and institutional backing to the partnership, including:

Mr. Alfred Lim, CEO of EUDA, commented, “This strategic expansion into T-cell immunotherapy represents a pivotal moment for EUDAas we continue to diversify our healthcare portfolio and deliver innovative solutions to our customers. By working with Shenzhen Innoand Keylock, we’re offering world-class immune-enhancing therapies to Malaysians at a fraction of traditional costs, furtheringour mission to transform the health and wellness landscape in the region, creating significant growth potential going forward.”

AboutEUDA Health Holdings Limited

EUDA Health Holdings Limited (NASDAQ: EUDA) is a Singapore-based leading non-invasive healthcare provider in Asia with a focus on Singapore, Malaysia, and China. The Company aims to become a market leader in non-invasive and preventive healthcare, with a strategic focus on the fast-growing longevity sector. Our mission is to address the evolving healthcare needs of over 1.8 billion people across the region which is experiencing significant demographic shifts as more than 30% of the population ages rapidly. By offering innovative, accessible, and science-backed health solutions, EUDA is positioned to lead the transformation of regional healthcare from reactive medical treatment to proactive, longevity-focused care. EUDA also runs a Singapore-based property management business.

ForwardLooking Statements

This document may contain forward-looking statements regarding risks and uncertainties. These statements usually use forward-looking words, such as the words “estimates,” “projected,” “expects,” “envisions,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions).These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside EUDA’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. You should not overly rely on forward-looking statements that are only applicable to the date of publication of this document. These forward-looking statements are based on information from EUDA and Shenzhen Inno, as well as other sources that we believe are reliable. The Company does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.